Galiximab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (primate/human) |
Target | CD80 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
|
Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, it is undergoing Phase III clinical trials.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]
References
External links
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.